Related Experiment Video
Updated: Jul 15, 2026
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
Published on: January 24, 2017
Update on therapeutic monoclonal antibodies
James B Bussel1, Lisa Giulino, Susan Lee
1Department of Pediatrics, Cornell University School of Medicine, New York, NY, USA.
Current Problems in Pediatric and Adolescent Health Care
|April 17, 2007
Summary
Monoclonal antibodies represent a significant advancement in medicine, evolving from laboratory tools to vital therapeutics. Their development since 1986 has revolutionized treatment options, with numerous antibodies now approved and more in development.
Area of Science:
- Immunology
- Pharmacology
- Biotechnology
Background:
- Monoclonal antibodies (mAbs) are a critical class of therapeutic drugs.
- Their therapeutic use began with the licensing of OKT4 in 1986.
- Prior to 1986, mAbs were primarily used in laboratory settings, such as the cluster designation (CD) system.
Purpose of the Study:
- To highlight the historical significance and evolution of monoclonal antibodies in medicine.
- To underscore the impact of monoclonal antibodies as therapeutic agents.
- To provide context on the development and application of monoclonal antibodies.
Main Methods:
- Historical review of monoclonal antibody development and licensing.
- Examination of the role of monoclonal antibodies in laboratory diagnostics.
- Analysis of the cluster designation (CD) system as an application.
Main Results:
- Eighteen additional therapeutic monoclonal antibodies have been licensed in the US since 1986.
- Numerous monoclonal antibodies are currently in development pipelines.
- The cluster designation (CD) system for hematopoietic cells now includes over 200 antigens.
Conclusions:
- Monoclonal antibodies have transformed the therapeutic landscape since their introduction.
- The continued development of monoclonal antibodies promises further medical advancements.
- Monoclonal antibodies have dual roles in both therapy and diagnostics.
Related Concept Videos
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...